EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Dovitinib Ameliorates Inflammation-Related Diseases by Inhibiting Necroptosis and Ferroptosis

Yingying Lin iD, Jianting Feng, Mingyuan Zhao, Libo Zhang, Yan Li, Xuan Chen, Chuibing Lin, Junxiong Lin, Qiaofa Lin, Jingyi Li, Lanqin Wu, Lisheng Li

ACS Chemical Biology · 2025

DOI: 10.1021/acschembio.5c00327 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Chemical Biology, 2025. Verfasst von Yingying Lin und 11 weiteren Autor:innen. Beteiligte Einrichtung: The School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350004, China. Hauptthemen laut MEDLINE: Ferroptosis, Necroptosis, Inflammation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fujian Medical University, Natural Science Foundation of Fujian Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Abnormal and dysregulated cell death plays important roles in organ injury. Necroptosis and ferroptosis are two distinct types of regulated cell death that can trigger inflammation and are involved in organ injury. The inhibition of necroptosis and ferroptosis is proposed to be beneficial for treating multiple pathological conditions. To find out necroptosis and ferroptosis inhibitors, we used a small-molecule compound library for screening and identified a clinically advanced compound, Dovitinib (Dov), as a potent dual inhibitor of necroptosis and ferroptosis. Dov inhibited tumor necrosis factor (TNF)-induced necroptosis by regulating receptor-interacting protein kinase 1 (RIPK1) and alleviated TNF-mediated systemic inflammatory response syndrome. Additionally, Dov inhibited ferroptosis by regulating the NRF2/HMOX1 axis and lipid peroxidation and protected against concanavalin A-induced acute liver injury. Thus, our work revealed that Dov is a dual inhibitor of necroptosis and ferroptosis and provides a potential therapeutic drug or combination approach for treating necroptosis- and ferroptosis-related diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisNecroptosisInflammationAnimalsHumansMiceMice, Inbred C57BLMaleReceptor-Interacting Protein Serine-Threonine KinasesTumor Necrosis Factor-alpha

Substanzen

Receptor-Interacting Protein Serine-Threonine KinasesTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • The School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350004, China.
  • Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, 1 Xueyuan Road, Minhou, Fuzhou 350004, China.

ORCID-Profile: Yingying Lin

Förderung

  • Fujian Medical University
  • Natural Science Foundation of Fujian Province
  • National Natural Science Foundation of China
  • Fujian Province

Zitieren

APA

Lin, Y., Feng, J., Zhao, M., Zhang, L., Li, Y., Chen, X., Lin, C., Lin, J., Lin, Q., Li, J., Wu, L., & Li, L. (2025). Dovitinib Ameliorates Inflammation-Related Diseases by Inhibiting Necroptosis and Ferroptosis. ACS Chemical Biology. https://doi.org/10.1021/acschembio.5c00327

Vancouver

Lin Y, Feng J, Zhao M, Zhang L, Li Y, Chen X, et al. Dovitinib Ameliorates Inflammation-Related Diseases by Inhibiting Necroptosis and Ferroptosis. ACS Chemical Biology. 2025. doi:10.1021/acschembio.5c00327

BibTeX
@article{Lin2025,
  author = {Lin, Yingying and Feng, Jianting and Zhao, Mingyuan and Zhang, Libo and Li, Yan and Chen, Xuan and Lin, Chuibing and Lin, Junxiong and Lin, Qiaofa and Li, Jingyi and Wu, Lanqin and Li, Lisheng},
  title = {Dovitinib Ameliorates Inflammation-Related Diseases by Inhibiting Necroptosis and Ferroptosis},
  journal = {ACS Chemical Biology},
  year = {2025},
  doi = {10.1021/acschembio.5c00327}
}
Kostenlos starten →